文献速递特殊人群用药

多发性硬化疾病修饰治疗的演变:药师更新

The evolution of multiple sclerosis disease-modifying therapies: An update for pharmacists.
PubMed 文献 · Am J Health Syst Pharm · 2024-01-01

本文讨论多发性硬化(MS)疾病修饰治疗(DMT)的演变及其适应症、作用机制、疗效、妊娠分级和成本。自1993年首个DMT问世以来,新类别DMT具有不同机制、更高疗效和更简便给药方案,但成本增加和处方限制成为缺点。药师可在MS患者管理中发挥重要作用。

要点

  • MS通常在20至40岁起病,可导致运动与认知缺陷及显著残疾。
  • 新型DMT提供更高疗效和更简便给药方案,但成本增加和处方限制影响使用。
  • 药师可在MS患者管理中发挥重要作用。

核心结论

  • 过去20年MS治疗格局显著变化,新型DMT为药师参与患者管理提供机会。

研究设计与样本

  • 本文为综述,讨论MS及DMT的演变、适应症、作用机制、疗效、妊娠分级和成本。

主要发现

  • MS是免疫介导的脱髓鞘进行性神经疾病,可导致运动和认知缺陷。
  • MS通常在20至40岁起病,随时间可导致显著残疾。
  • 自1993年首个DMT引入以来,新类别DMT具有不同作用机制、更高疗效和更简便给药方案。
  • DMT的缺点包括成本增加和处方限制。

临床怎么用

  • 药师应了解DMT的适应症、机制、疗效、妊娠分级和成本,以参与MS患者管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Multiple sclerosis (MS) and the evolution of disease-modifying therapies (DMTs) and their indications, mechanisms of action, efficacy, pregnancy class, and cost are discussed. SUMMARY: MS is an immune-mediated, demyelinating, and progressive neurological disorder that can cause both motor and cognitive deficits. Onset of MS typically occurs between the ages of 20 and 40 years, and the disease can result in significant disability over time. Since the introduction of the first DMT for the treatment of MS in 1993, significant progress has been made in the development of new classes of DMTs with different mechanisms of action, higher efficacy, and simpler administration schedules, offering patients better alternatives. However, drawbacks with the use of DMTs include their increasing cost and formulary restrictions. CONCLUSION: The treatment landscape of MS has significantly changed over the past 2 decades, and the introduction of newer classes of DMTs provides an opportunity for pharmacists to play an important role in the management of this patient population.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Edinger A, Habibi M. The evolution of multiple sclerosis disease-modifying therapies: An update for pharmacists. Am J Health Syst Pharm. 2024. PMID: 37777869. doi:10.1093/ajhp/zxad247

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。